# EDGAR Filing Document

**Accession Number:** 0001479915
**File Stem:** 0001493152-26-009006
**Filing Date:** 2026-3
**Character Count:** 12150
**Document Hash:** 9f4748e26ebcabc16fe14bf96f839d95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-009006.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001493152-26-009006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260305

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CQENS Technologies Inc.
- **CENTRAL INDEX KEY:** 0001479915
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271521364
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55470
- **FILM NUMBER:** 26726937

**BUSINESS ADDRESS:**
- **STREET 1:** 5550 NICOLLET AVENUE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55419
- **BUSINESS PHONE:** 612-812-2037

**MAIL ADDRESS:**
- **STREET 1:** 5550 NICOLLET AVENUE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VapAria Corp
- **DATE OF NAME CHANGE:** 20140820

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OICco ACQUISITION IV, INC.
- **DATE OF NAME CHANGE:** 20100105

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**: March 5, 2026

**CQENS Technologies Inc.**

*(Exact name of registrant as specified in its charter)*

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-55470** | **27-1521407** |
| *(State or other jurisdiction of*<br> *incorporation or organization)* | *(Commission*<br> *File Number)* | *(I.R.S. Employer*<br> *Identification No.)* |

---

**170 S Green Valley Parkway**

**Suite 343**

**Henderson, NV 89012**

*(Address of principal executive offices Zip Code)*

 

Registrant's telephone number, including area code: 702-661-2404

*(Former name or former address, if changed since last report)*

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which** **registered** |
| None | Not applicable | Not applicable |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 3(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective March 5, 2026, CQENS Technologies Inc. (the "Company"), appointed the following individuals to serve as officers of the Company as follows: (i) Markus Bonke - Chief Operating Officer; (ii) Titus Wouda Kuipers - Chief Commercial Officer; (iii) Ged Shudall - Chief Technology Officer; and (iv) William Bartkowski - Chief Administrative Officer. In addition to his new appointment as Chief Administrative Officer, Mr. Bartkowski will continue in his role as Corporate Secretary.

The new officers are currently serving the Company at will for compensation to be determined. The Company may enter into employment agreements with such individuals in the future.

There are no arrangements or understandings between the newly-appointed and currently-serving officers and any other persons, pursuant to which they were selected in their roles, no family relationships among any of the Company's directors or executive officers and the officers, and there are no related party transactions involving the officers that would require disclosure under Item 404(a) of Regulation S-K.

**Item 7.01** **Regulation FD Disclosure.**

On March 5, 2026, the Company. distributed a letter to its shareholders of record as of March 5, 2026 providing a review of the company's recent developments and overview and update on the Company's plan of operations. A copy of this letter is furnished as Exhibit 99.1 to this report.

Pursuant to General Instruction B.2 of Form 8-K, the information in this Item 7.01 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the company under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01** **Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| **No.** | **Exhibit Description** |
| 99.1 | [Letter to Shareholders dated March 5, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | CQENS TECHNOLOGIES INC. | CQENS TECHNOLOGIES INC. |
| Date: March 5, 2026 | By: | */s/ William P. Bartkowski* |
|  |  | William P. Bartkowski, Chief Administrative Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

March 5, 2026

To Our Shareholders,

The past eight months have seen CQENS make significant progress toward our goal of expanding our valuable, worldwide Intellectual Property ("IP") portfolio, securing US FDA authorization to launch a modified risk tobacco product in the US, and making significant progress with respect to listing our shares for trading in the public market.

In terms of our Intellectual Property ("IP"), during the recent period, we have added to our patent portfolio in the US and in countries in Asia and throughout the European Union. This is in keeping with our strategy of focusing our IP efforts on building a broad and deep "moat" to safeguard the design and the details of our proprietary, patented, and patent pending Heated Tobacco Product ("HTP"),

On the US regulatory front, we met with the FDA late in 2025. It is the responsibility of the FDA to thoroughly review our Pre-market Tobacco Authorization ("PMTA"), and to make the determination as to whether we secure the necessary authorization to launch our HTP in the US. In addition, it is important to note that the PMTA is the "gold standard" for international authorization and approval.

Our PMTA submission also requires significant detail as to where and how we will manufacture the key components of our HTP. We now expect to manufacture our devices in Hong Kong and our US tobacco consumables in the US. To support these initiatives, we have established a product realization center in Shenzhen, China, for the device, and we will be occupying a new facility in North Carolina to manufacture the tobacco consumables.

Our next meeting with the FDA is scheduled to take place this month, and our team is well into its preparations for this meeting. Regular sessions for interaction and feedback from our regulators are essential as we prepare our PMTA for submission and we are pleased that the current FDA leadership and staff concur.

To achieve certain critical goals, in late 2025 we engaged Jefferies, an international investment banker with both broad and recent experience in the tobacco industry. They have been engaged to assist us in identifying and undertaking certain corporate growth strategies, including those that would lead to the listing of our Common Stock for trading. However, there are no assurances that Jefferies will identify any suitable strategies or that we will complete such strategies.

To further support our efforts to secure FDA authorization, list our shares, and launch a product in the US, we have also made three important additions to our senior management team. These three executives were recently senior executives at Imperial Brands PLC, one of the world's largest tobacco companies. This experienced team of executives have joined the Company for future considerations yet to be determined.

The team is comprised of Titus Wouda Kuipers, who is serving as our Chief Commercial Officer, Markus Bonke, serving as our Chief Operating Officer, and Ged Shudall, serving as our Chief Technology Officer. Titus has held senior commercial leadership roles, including responsibilities relating to next-generation tobacco product categories. His experience includes global commercial strategy, market entry planning, and the development and scaling of reduced-risk product portfolios across multiple international markets. Markus has delivered large-scale business transformations, leading people, and global operational work streams in major change programs, including mergers and acquisition integration, market entries, and the rollouts of new business models; and Ged is an engineer with more than three decades of experience in tobacco-related product development and manufacturing systems. He held senior technical and engineering leadership roles involving the design, development, and implementation of manufacturing processes and specialized machinery for both combustible and next-generation tobacco products.

As you can see, we believe 2026 will be an exciting and momentous year for CQENS. I look forward to providing you with additional updates as the year progresses and remind you to review our reports filed with the Securities and Exchange Commission ("SEC"). Thank you for your confidence and your support during these important times for CQENS.

Sincerely

![](ex99-1_002.jpg)

Alexander Chong

Chairman and Chief Executive Office

This correspondence contains statements, estimates, forecasts, and projections regarding future performance and events that constitute "forward-looking statements". Those statements include statements regarding anticipated growth strategy and product development and approval. These statements may be identified by the use of words like "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "will", "should", and "seek", and similar expressions and include any financial projections or estimates. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those projected in the forward-looking statements. Important factors and risks that could cause actual results to differ materially from our expectations include, but are not limited to, regulatory issues and approvals, working capital requirements and product development, as well as those risks detailed in our filings with the SEC, including our most recent Form 10-K and other filings with the SEC. Please review our reports filed with the SEC for additional information regarding CQENS.